The Kutcher Generalized Social Anxiety Disorder Scale for Adolescents: assessment of its evaluative properties over the course of a 16-week pediatric psychopharmacotherapy trial
- PMID: 15319024
- DOI: 10.1089/1044546041649002
The Kutcher Generalized Social Anxiety Disorder Scale for Adolescents: assessment of its evaluative properties over the course of a 16-week pediatric psychopharmacotherapy trial
Abstract
Objective: This study investigated the psychometric properties of a new clinician-rated scale designed to assess the severity of social phobia and measure treatment outcome in adolescents: the Kutcher Generalized Social Anxiety Disorder Scale for Adolescents (K-GSADS-A).
Methods: Two hundred fifty-one (251) adolescents (11-17 years; mean age 14.2 years) with DSM-IV social phobia enrolled in a multicenter, 16-week, double-blind, placebo-controlled study of paroxetine. Efficacy assessments were conducted at baseline and at weeks 4, 8, 12, and 16 with the K-GSADS-A, three other clinician-rated scales (including the Clinical Global Impression of Severity scale), and a self-rated social phobia scale. Additionally, the Clinical Global Impression of Improvement scale was administered at each postbaseline assessment, and the Children's Depression Rating Scale-Revised was administered at baseline and at week 16. These data were used to assess the internal consistency, convergent and divergent validity, and sensitivity to change of the K-GSADS-A.
Results: The internal consistency of the K-GSADS-A was adequate, and supportive evidence was obtained for its convergent validity with other severity measures, and its divergent validity with respect to depression. The K-GSADS-A also demonstrated good sensitivity to changes in severity.
Conclusions: These results suggest that the K-GSADS-A is a valid measure of treatment outcome in adolescents with DSM-IV social phobia.
Similar articles
-
Evidence based clinical assessment of child and adolescent social phobia: a critical review of rating scales.Child Psychiatry Hum Dev. 2012 Oct;43(5):795-820. doi: 10.1007/s10578-012-0297-y. Child Psychiatry Hum Dev. 2012. PMID: 22438106 Review.
-
The Kutcher Adolescent Depression Scale: assessment of its evaluative properties over the course of an 8-week pediatric pharmacotherapy trial.J Child Adolesc Psychopharmacol. 2003 Fall;13(3):337-49. doi: 10.1089/104454603322572679. J Child Adolesc Psychopharmacol. 2003. PMID: 14642022 Clinical Trial.
-
Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.Hum Psychopharmacol. 2004 Aug;19(6):387-96. doi: 10.1002/hup.602. Hum Psychopharmacol. 2004. PMID: 15303242 Clinical Trial.
-
Psychometric properties of the Japanese version of the Social Phobia Inventory.Psychiatry Clin Neurosci. 2013 Apr;67(3):160-6. doi: 10.1111/pcn.12037. Psychiatry Clin Neurosci. 2013. PMID: 23581867
-
Advances in recognition and treatment of social anxiety disorder: a 10-year retrospective.Psychopharmacol Bull. 2003 Spring;37 Suppl 1:97-107. Psychopharmacol Bull. 2003. PMID: 14566205 Review.
Cited by
-
Clinical Considerations for an Evidence-Based Assessment of Anxiety Disorders in Children and Adolescents.Psychiatr Clin North Am. 2024 Dec;47(4):641-672. doi: 10.1016/j.psc.2024.04.010. Epub 2024 May 28. Psychiatr Clin North Am. 2024. PMID: 39505446 Review.
-
Evidence based clinical assessment of child and adolescent social phobia: a critical review of rating scales.Child Psychiatry Hum Dev. 2012 Oct;43(5):795-820. doi: 10.1007/s10578-012-0297-y. Child Psychiatry Hum Dev. 2012. PMID: 22438106 Review.
-
Rating scales for anxiety/anxiety disorders.Curr Psychiatry Rep. 2007 Aug;9(4):271-7. doi: 10.1007/s11920-007-0032-8. Curr Psychiatry Rep. 2007. PMID: 17880857 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical